European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 639-645 , July 2010

The impact of young age on breast cancer outcome

  • L. Livi

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • I. Meattini

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 055 7947719; fax: +39 055 4379930.
    • ,
  • C. Saieva

      Affiliations

    • Molecular and Nutritional Epidemiology Unit, ISPO, Cancer Prevention and Research Institute, Florence, Italy
    • ,
  • S. Borghesi

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • V. Scotti

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • A. Petrucci

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • A. Rampini

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • L. Marrazzo

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • V. Di Cataldo

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
    • ,
  • S. Bianchi

      Affiliations

    • Department of Pathology, University of Florence, Florence, Italy
    • ,
  • L. Cataliotti

      Affiliations

    • Department of Surgery, University of Florence, Florence, Italy
    • ,
  • G. Biti

      Affiliations

    • Department of Radiation–Oncology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy

,Accepted 4 May 2010.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106–130
  2. Zekri JM, El-Helw LM, Purohit OP, et al. Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function. Clin Oncol. 2008;20:513–516
  3. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672–1694
  4. Hickey M, Peate M, Saunders CM, et al. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323–339
  5. Olivotto IA, Bajdik CD, Plenderleith IH, et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med. 1994;330:805
  6. Pagani O, Goldhirsch A. Breast cancer in young women: climbing for progress in care and knowledge. Womens Health. 2006;2:717–732
  7. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000;355:1869–1874
  8. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261
  9. Bernstein V. How young is too young? The impact of age on premenopausal breast cancer prognosis. Breast Cancer Res Treat. 2002;76:A137
  10. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–3330
  11. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–2581
  12. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18:296–306
  13. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:71–85
  14. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;19:930–942
  15. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–1496
  16. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658
  17. Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005;23:8313–8321
  18. Clarke M, Coates AS, Darby SC, et al. Early Breast Cancer Trialists’ Collaborative Group Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29–40
  19. Papaldo P, Di Cosimo S, Ferretti G, et al. Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. Breast. 2006;15:269–272
  20. Henderson IC, Berry DA, Demetri GD, et al. Improved outcome from adding sequential paclitaxel but not escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  21. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–1671
  22. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  23. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol. 2006;24:1332–1341
  24. Kyndi M, Overgaard M, Nielsen HM, et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90:74–79

PII: S0748-7983(10)00124-1

doi: 10.1016/j.ejso.2010.05.016

European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 639-645 , July 2010

Article Tools

* Image Usage & Resolution